 | • レポートコード：MRC2111A050 • 出版社/出版日：Transparency Market Research / 2021年8月30日 • レポート形態：英文、PDF、225ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、創薬におけるAIの世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、提供別（ソフトウェア、サービス）分析、技術別分析、薬剤タイプ別分析、用途別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・創薬におけるAIの世界市場規模：提供別（ソフトウェア、サービス） ・創薬におけるAIの世界市場規模：技術別 ・創薬におけるAIの世界市場規模：薬剤タイプ別 ・創薬におけるAIの世界市場規模：用途別 ・創薬におけるAIの世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
AI in Drug Discovery Market – Scope of Report
TMR’s report on the global AI in drug discovery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global AI in drug discovery market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global AI in drug discovery market from 2021 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the AI in drug discovery market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global AI in drug discovery market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global AI in drug discovery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global AI in drug discovery market.
The report delves into the competitive landscape of the global AI in drug discovery market. Key players operating in the global AI in drug discovery market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global AI in drug discovery market profiled in this report.
Key Questions Answered in AI in Drug Discovery Market Report
What is the sales/revenue generated by the AI in drug discovery market across all regions during the forecast period?
What are the opportunities in the global AI in drug discovery market?
What are the major drivers, restraints, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which drug type segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
AI in Drug Discovery Market – Research Objectives and Research Approach
The comprehensive report on the global AI in drug discovery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global AI in drug discovery market in terms of offering, technology, drug type, application, end user, and region. Key segments under each criterion are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global AI in drug discovery market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global AI in Drug Discovery Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global AI in Drug Discovery Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid /long term impact)
6. Global AI in Drug Discovery Market Analysis and Forecast, by Offering
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Offering, 2017–2031
6.3.1. Software
6.3.2. Services
6.4. Market Attractiveness Analysis, by Offering
7. Global AI in Drug Discovery Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Machine Learning
7.3.2. Other Technologies
7.4. Market Attractiveness Analysis, by Technology
8. Global AI in Drug Discovery Market Analysis and Forecast, by Drug Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Drug Type, 2017–2031
8.3.1. Small Molecules
8.3.2. Large Molecules
8.4. Market Attractiveness Analysis, by Drug Type
9. Global AI in Drug Discovery Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Oncology
9.3.2. Infectious Diseases
9.3.3. Neurological Disorders
9.3.4. Rare Diseases
9.3.5. Metabolic Diseases
9.3.6. Cardiovascular Diseases
9.3.7. Others
9.4. Market Attractiveness Analysis, by Application
10. Global AI in Drug Discovery Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Research Organizations
10.3.3. Academics & Research
10.3.4. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global AI in Drug Discovery Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America AI in Drug Discovery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Offering, 2017–2031
12.2.1. Software
12.2.2. Services
12.3. Market Value Forecast, by Technology, 2017–2031
12.3.1. Machine Learning
12.3.2. Other Technologies
12.4. Market Value Forecast, by Drug Type, 2017–2031
12.4.1. Small Molecules
12.4.2. Large Molecules
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Oncology
12.5.2. Infectious Diseases
12.5.3. Neurological Disorders
12.5.4. Rare Diseases
12.5.5. Metabolic Diseases
12.5.6. Cardiovascular Diseases
12.5.7. Others
12.6. Market Value Forecast, by End-user, 2017–2031
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Research Organizations
12.6.3. Academics & Research
12.6.4. Others
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Offering
12.8.2. By Technology
12.8.3. By Drug Type
12.8.4. By Application
12.8.5. By End-user
12.8.6. By Country
13. Europe AI in Drug Discovery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Offering, 2017–2031
13.2.1. Software
13.2.2. Services
13.3. Market Value Forecast, by Technology, 2017–2031
13.3.1. Machine Learning
13.3.2. Other Technologies
13.4. Market Value Forecast, by Drug Type, 2017–2031
13.4.1. Small Molecules
13.4.2. Large Molecules
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Oncology
13.5.2. Infectious Diseases
13.5.3. Neurological Disorders
13.5.4. Rare Diseases
13.5.5. Metabolic Diseases
13.5.6. Cardiovascular Diseases
13.5.7. Others
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Research Organizations
13.6.3. Academics & Research
13.6.4. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Offering
13.8.2. By Technology
13.8.3. By Drug Type
13.8.4. By Application
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific AI in Drug Discovery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Offering, 2017–2031
14.2.1. Software
14.2.2. Services
14.3. Market Value Forecast, by Technology, 2017–2031
14.3.1. Machine Learning
14.3.2. Other Technologies
14.4. Market Value Forecast, by Drug Type, 2017–2031
14.4.1. Small Molecules
14.4.2. Large Molecules
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Oncology
14.5.2. Infectious Diseases
14.5.3. Neurological Disorders
14.5.4. Rare Diseases
14.5.5. Metabolic Diseases
14.5.6. Cardiovascular Diseases
14.5.7. Others
14.6. Market Value Forecast, by End-user, 2017–2031
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Research Organizations
14.6.3. Academics & Research
14.6.4. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. Japan
14.7.2. China
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Offering
14.8.2. By Technology
14.8.3. By Drug Type
14.8.4. By Application
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America AI in Drug Discovery Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Offering, 2017–2031
15.2.1. Software
15.2.2. Services
15.3. Market Value Forecast, by Technology, 2017–2031
15.3.1. Machine Learning
15.3.2. Other Technologies
15.4. Market Value Forecast, by Drug Type, 2017–2031
15.4.1. Small Molecules
15.4.2. Large Molecules
15.5. Market Value Forecast, by Application, 2017–2031
15.5.1. Oncology
15.5.2. Infectious Diseases
15.5.3. Neurological Disorders
15.5.4. Rare Diseases
15.5.5. Metabolic Diseases
15.5.6. Cardiovascular Diseases
15.5.7. Others
15.6. Market Value Forecast, by End-user, 2017–2031
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Research Organizations
15.6.3. Academics & Research
15.6.4. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Offering
15.8.2. By Technology
15.8.3. By Drug Type
15.8.4. By Application
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa AI in Drug Discovery Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Offering, 2017–2031
16.2.1. Software
16.2.2. Services
16.3. Market Value Forecast, by Technology, 2017–2031
16.3.1. Machine Learning
16.3.2. Other Technologies
16.4. Market Value Forecast, by Drug Type, 2017–2031
16.4.1. Small Molecules
16.4.2. Large Molecules
16.5. Market Value Forecast, by Application, 2017–2031
16.5.1. Oncology
16.5.2. Infectious Diseases
16.5.3. Neurological Disorders
16.5.4. Rare Diseases
16.5.5. Metabolic Diseases
16.5.6. Cardiovascular Diseases
16.5.7. Others
16.6. Market Value Forecast, by End-user, 2017–2031
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Research Organizations
16.6.3. Academics & Research
16.6.4. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Offering
16.8.2. By Technology
16.8.3. By Drug Type
16.8.4. By Application
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2020
17.3. Company Profiles
17.3.1. Exscientia
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Company Financials
17.3.1.3. Growth Strategies
17.3.1.4. SWOT Analysis
17.3.2. GNS Healthcare
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Company Financials
17.3.2.3. Growth Strategies
17.3.2.4. SWOT Analysis
17.3.3. Cloud Pharmaceuticals, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Company Financials
17.3.3.3. Growth Strategies
17.3.3.4. SWOT Analysis
17.3.4. Benevolent AI
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Company Financials
17.3.4.3. Growth Strategies
17.3.4.4. SWOT Analysis
17.3.5. PathAI, Inc.
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Company Financials
17.3.5.3. Growth Strategies
17.3.5.4. SWOT Analysis
17.3.6. Berg Health
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Company Financials
17.3.6.3. Growth Strategies
17.3.6.4. SWOT Analysis
17.3.7. Atomwise
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Company Financials
17.3.7.3. Growth Strategies
17.3.7.4. SWOT Analysis
17.3.8. Insitro
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Company Financials
17.3.8.3. Growth Strategies
17.3.8.4. SWOT Analysis
17.3.9. Cyclica
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Company Financials
17.3.9.3. Growth Strategies
17.3.9.4. SWOT Analysis
17.3.10. BlackThorn Therapeutics
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Company Financials
17.3.10.3. Growth Strategies
17.3.10.4. SWOT Analysis
17.3.11. Insilico Medicine
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Company Financials
17.3.11.3. Growth Strategies
17.3.11.4. SWOT Analysis
17.3.12. Notable Labs
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Company Financials
17.3.12.3. Growth Strategies
17.3.12.4. SWOT Analysis
17.3.13. Standigm
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Company Financials
17.3.13.3. Growth Strategies
17.3.13.4. SWOT Analysis
17.3.14. Recursion Pharmaceuticals
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Company Financials
17.3.14.3. Growth Strategies
17.3.14.4. SWOT Analysis
17.3.15. BioSymetrics
17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.15.2. Company Financials
17.3.15.3. Growth Strategies
17.3.15.4. SWOT Analysis
Table 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Offering, 2017–2031
Table 02: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 03: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 04: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 09: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 10: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 15: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 16: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 17: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 21: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 22: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 23: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 27: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 28: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 29: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 32: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 33: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 34: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 35: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031